Loading...
Patients with cancer (especially epithelial malignancies such as prostate cancer) are at excess risk for thromboembolic events. Risk among patients with prostate cancer might be further elevated by androgen-deprivation therapy (ADT), which has been linked to risk for deep venous thrombosis (DVT) and pulmonary embolism (PE). Given more widespread use of ADT for nonmetastatic prostate cancer (as well as traditional use for metastatic disease) and longer treatment durations, evaluating thromboembolic risks has become even more important.
Using data from the National Prostate Cancer Register of Sweden (from 1997 through 2007), investigators assessed risk for thromboembolic events among 76,600 prostate cancer patients. Seventeen percent of patien…